In vitro studies have described the anti-inflammatory effects of CBD (Esposito et al., 2006a; Esposito et al., 2006b; Martín-Moreno et al., 2011), however, recent in vivo studies have failed to relate these effects with a reversion of cognitive impairments in animal models of AD (Cheng et al., 2014a; Cheng et al., 2014b; Watt et al., 2020) which may indicate that CB1 and CB2 receptors play a crucial role in the cognitive impairments induced by the inflammatory response and they are potential therapeutic targets to take into account in future experiments. The gene discussed is CNR1; the disease is Cognitive impairment.